Industry News

• KaloBios to change company name to Humanigen, Inc.  KaloBios Pharmaceuticals announced it will change the company’s name to Humanigen, Inc. The company’s stock will also begin trading under the new ticker symbol HGEN on the OTCQB market as of the opening on August 7, 2017.
  July 27, 2017  
• FDA grants priority review for Amgen's sBLA for Repatha® (evolocumab)  Amgen announced the FDA has granted priority review for Amgen's sBLA for Repatha® (evolocumab), a PCSK9 inhibitor. If approved by the FDA, the Prescribing Information will be updated to include risk reduction of major cardiovascular events based on data from the large FOURIER study.
  July 27, 2017  
• Southwestern researchers find link between immune defense, mutation in Crohn’s disease  Genes that regulate a cellular recycling system called autophagy are commonly mutated in Crohn’s disease patients, though the link between biological housekeeping and inflammatory bowel disease remained a mystery. Now, researchers at Southwestern Medical Center have uncovered an intriguing clue.
  July 27, 2017  
• Immune system may mount an attack in Parkinson’s disease  A new study suggests that T cells, which help the body’s immune system recognize friend from foe, may play an important role in Parkinson’s disease. The study, supported by the National Institute of Neurological Disorders and Stroke results, was published in the journal Nature.
  July 27, 2017  
• TESARO and Takeda enter into exclusive licensing agreement for cancer therapy niraparib  TESARO and Takeda announced an exclusive licensing agreement for commercialization and clinical development of niraparib, a poly ADP-ribose polymerase inhibitor. The agreement includes development of niraparib for treatment of all tumor types in Japan, South Korea, Taiwan, Russia and Australia.
  July 27, 2017  
• Boston Scientific announces results for second quarter 2017  Boston Scientific reported GAAP earnings of $146 million or $0.11 per share in the 2017 second quarter, versus a GAAP loss of $207 million or $(0.15) a year ago, and achieved adjusted EPS of $0.32 for the period, versus $0.27 a year ago.
  July 27, 2017  
• Baxter completes acquisition of Claris Injectables, expanding generic injectable medicines  Baxter announced the completion of the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company. With this acquisition, Baxter gains access to the complete Claris Injectables product portfolio and pipeline as well as three manufacturing plants.
  July 27, 2017  
• NewLink Genetics announces first patient dosed in phase 1 study of IDO pathway inhibitor  NewLink Genetics announced first patient dosed in the Phase 1 study of NLG802, a novel prodrug of indoximod. NLG802 is an investigational agent targeting the IDO pathway and represents an important step in the company's strategic planning and intellectual property management.
  July 27, 2017  
• Arbutus announces conclusion of LNP license agreement with Alexion   Arbutus Biopharma announced it has received notice of termination from Alexion Pharmaceuticals for the companies' LNP license agreement, which was signed and announced in March 2017. Alexion's termination of the LNP license agreement was driven by a strategic review of Alexion's business portfolio.
  July 27, 2017  
• Eiger announces FDA Fast Track designation granted for Pegylated Interferon Lambda  Eiger BioPharmaceuticals announced the FDA has granted Fast Track designation for pegylated interferon lambda 1a as a potential treatment for chronic hepatitis delta virus infection. Eiger licensed worldwide rights to Lambda from Bristol-Myers Squibb in April 2016.
  July 27, 2017  

   (next 10 articles)